Regarding the presence of metastases (M), 36 of the HER2-positive patients (80%) did not have metastatic disease at diagnosis after performing imaging investigations (abdominal–pelvic CT scan, bone scintigraphy as appropriate, brain or bone MRI). Here, ERBB2 is linked to metastatic neoplasm.